ABERDEEN 6 SEPTEMBER 2023. NovaBiotics, the clinical-stage biotechnology company announces the appointment of Dr Trevor Phillips to its board as Non-Executive Director.
Trevor is a biotechnology leader who previously held board and C-level roles in pharma and Biotech in Europe and the US, managing both private and public companies. Trevor’s experience in business strategy, research and development, product commercialization and corporate development, including, fundraising, IPO, M&A, and licensing, further strengthens the NovaBiotics’ board as the company moves into a key phase with market launch of its nail disorder product anticipated in 2024. In addition, the company is actively fundraising and in discussions with a number of potential strategic partners who have approached the Company with interest in NovaBiotics’ cysteamine platform and the advanced-stage clinical assets developed from that technology.
Dr Phillips commented, “I am very excited to be joining the Board of NovaBiotics at this pivotal time in the Company’s development” and Bryan Bodek, NovaBiotics chairman stated, “We are delighted to welcome Trevor to the board at such a potentially transformational period for the business. Trevor’s sector-specific expertise will bolster the team and his proven track-record is evident from the successful life science businesses he has played a role in both in the US and UK. We all look forward to working with him”.
NovaBiotics Ltd www.novabiotics.co.uk is a clinical-stage biotechnology company designing and developing highly disruptive, much needed solutions for health and personal care. The company’s advanced-stage assets include a nail disorder product with anticipated market launch in 2024 and a phase 3 pneumonia product candidate, NM002 on which peer-reviewed data to support its anti-inflammatory and anti-viral mechanisms has recently been published Publication of NovaBiotics’ research – Novabiotics.
About Dr Trevor Phillips
Trevor’s board and C-level leadership roles span small and large, privately held and listed companies including executive positions at NEPeSMO, Open Orphan PLC (formerly hVIVO Group PLC before Trevor took the helm, led a successful re-positioning of the business and its subsequent acquisition by Open Orphan, creating significant shareholder value), Vectura Goup PLC (where he was part of a major capital raise to facilitate strategic acquisitions) and Critical Therapeutics (where he managed the majority of business functions that led to the successful approval and commercial launch of a respiratory product and subsequent acquisition of the business by Cornerstone Therapeutics, now part of Chiesi Pharma) and additionally, board positions at Morvus Technologies and Tissue Regenix. Trevor trained as a microbiologist and so importantly brings his scientific background to the board as well his commercial skills and experience.
For further information please contact:
NovaBiotics WG Partners – Financial Advisors to NovaBiotics
Dr Deborah O’Neil David Wilson, Nigel Barnes, Jacob Masters
+44 (0)1224 711377 +44 (0) 203 705 9321